ClinicalTrials.gg
CompletedNCT02447328Updated Sep 5, 2021Results posted

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

A Phase 4 interventional study of Fulvestrant in Locally Advanced or and Metastatic Breast Cancer, sponsored by AstraZeneca. Completed at 9 sites in Korea, Republic of. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-09-05.

Sponsored by AstraZeneca · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
83
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Enrollment
45th of 94
83 · median 71
Started
2015
with 5 others
Phase 4
4 of 95
1 open now
Registered
52nd of 95
by date
Lead sponsor
18 of 95
AstraZeneca

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 45th largest by enrollment of the 94 interventional ones that give a count, is one of 6 that started in 2015, is one of 4 in phase 4, and was the 52nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This single-arm study aims to assess the safety and tolerability profile of Fulvestrant(Faslodex®) as 2nd line and later therapy in postmenopausal women with locally advanced or metastatic breast cancer. The primary objective is to evaluate the adverse events after Fulvestrant (Faslodex®) for about 6 months

Read the detailed description

This study is a Phase 4, single-arm, safety and tolerability study of fulvestrant (Faslodex®) as 2nd line therapy in postmenopausal women with locally advanced or metastatic breast cancer.

All of enrolled patients in this study will be injected fulvestrant (Faslodex®). This study will be performed for about 3 years and approximately 100 patients(actual target will be 80 treated patients) will be enrolled in about 10 investigational sites.

After obtaining the written informed consent from the patients, the information of demographic and medical history will be collected and laboratory tests will be performed.

Patients who meet the inclusion/exclusion criteria will be injected the fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection. The information of adverse events will be collected after the 1st dose of IP injection. In case that the evaluation of tumor response might be performed in regular clinical practice, those data will also be collected as well. The quality of life will also be measured.

03

Conditions studied

  • Locally Advanced or
  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Post menopausal status women
  • Outpatient or inpatient with locally advanced or breast cancer who have failed with prior anti-estrogen therapy.
  • Estrogen receptor positive
  • Radiographic progression of disease after the prior therapy
  • Patients who agree to participate in this study and sign the

Exclusion criteria

Exclusion Criteria:

  • Patients who are treated with fulvestrant
  • Patients who are being treated with the other antitumor agents
  • Pregnancy or lactating women
  • History of to any of included ingredients (eg. Castor oil)
  • Patients who are considered not fit for the study by investigators
  • Patients who have severe dysfunction of liver or kidney
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Single Arm

    Faslodex treated in the study

    Drug: Fulvestrant

Interventions

  • fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection.

06

What researchers measure

Primary outcomes

  1. Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions)

    Percentage of patients with AEs.

    Time frame: Adverse events were collected from treatment initiation to end of the study about 6 months for each patient.

07

Results

Posted Mar 22, 2018
Limitations and caveats
less information in efficacy set.

Participant flow

First subject enrolled: 29MAY2015 Last subject last visit: 06MAY2016 This study was conducted from 29 May 2015 to 06 May 2016 and 85 subjects from 9 study centres participated.

Participant flow — Overall Study
MilestoneSingle Arm
Started83
Completed82
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimarySafety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions)

Percentage of patients with AEs.

Time frame:
Adverse events were collected from treatment initiation to end of the study about 6 months for each patient.
Reported as:
Number · Percentage of participants
Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions)
Percentage of participantsSingle Arm
Adverse Events(AE)81.5 (71.3 to 89.3)
ADR; based on current South Korea label.38.3 (27.7 to 49.7)
Serious AE11.1 (5.2 to 20.1)
Serious ADR0 (0 to 4.4)
Unexpected AE71.6 (60.5 to 81.1)
Unexpected ADR24.7 (15.8 to 35.5)

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Arm—9/81 (11.1%)66/81 (81.5%)
Most frequent serious events
Most frequent serious events
EventSingle Arm
CHOLANGITISHepatobiliary disorders1/81
contusion of brainInjury, poisoning and procedural complications1/81
HydronephrosisRenal and urinary disorders1/81
Blood creatinine increasedInvestigations1/81
Acute lymphocytic leukaemia (in remission)Neoplasms benign, malignant and unspecified (incl cysts and polyps)1/81
Joint DislocationInjury, poisoning and procedural complications1/81
Bone PainMusculoskeletal and connective tissue disorders1/81
pelvic painReproductive system and breast disorders1/81
Most frequent other events
Showing 10 of 15
Most frequent other events
EventSingle Arm
nauseaGastrointestinal disorders10/81
MyalgiaMusculoskeletal and connective tissue disorders10/81
back painGeneral disorders9/81
dizzinessNervous system disorders9/81
ConstipationGastrointestinal disorders7/81
headacheNervous system disorders7/81
PainGeneral disorders6/81
AnorexiaGastrointestinal disorders6/81
arthralgiaMusculoskeletal and connective tissue disorders6/81
upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders6/81

Baseline characteristics

In this study, a total of 85 subjects were enrolled, and 83 of them received study drug open labelled, single arm. The safety population included 81 subjects who met all of the inclusion/exclusion criteria, and 74 of them were included in the efficacy population.

Age, Continuous
Age, Continuous(years)Single Arm
Age56.6 ± 9.34
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm
Female81
Male0
08

Study locations

9 sites
  • Research Site
    Cheongju-si, 28644, Korea, Republic of
  • Research Site
    Daegu, 41404, Korea, Republic of
  • Research Site
    Goyang-si, 10408, Korea, Republic of
  • Research Site
    Seo-Gu, 49241, Korea, Republic of
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
09

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in May 2016, 11 months.

Results were first posted in Mar 2018, 1 year 10 months after primary completion.

Of 130 phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2015
First posted
May 18, 2015
StartActual
May 29, 2015
Primary completionActual
May 6, 2016
CompletionActual
Sep 16, 2020
Results first posted
Mar 22, 2018
Last update
Sep 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02447328
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 18, 2015
Start date
May 29, 2015
Primary completion
May 6, 2016
Completion
Sep 16, 2020
Results posted
Mar 22, 2018
Last update
Sep 5, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion